The UEA small RNA Workbench is a suite of tools for analyzing micro RNA and other small RNA data from High-Throughput Sequencing devices.  For a quick overview of what the UEA sRNA Workbench can do for you, and which tool you should select for the task, please visit this page.

Latest release is version 4.2 alpha which is released as java binaries only to streamline the release process until the software moves into the stable release stage of its lifecycle.

Download 4.2 alpha

Changes include:


  1. All linux binaries are now compiled as 64bit removing the need to install the 32bit libraries prior to running the software
  2. Bug fixes and stability improvements

miRCat 1 (Version 3.2)

  1. Fixed the show genome browser view

RNA Annotation

  1. Fixed the issues with hairpin sequences not rendering


  1. Fixed the issues with the VisSR tool not having required resources included within the most recent build


  1. Chromosome headers can now be much longer than in previous versions (very long chromosome headers such as those found in scaffolded files caused the software to crash)


International Journal of Molecular SciencesThe International Journal of Molecular Sciences (Impact Factor3.257 (2015); 5-Year Impact Factor: 3.213 (2015)) is working on a Special Issue ” MicroRNA Regulation 2017” and is calling for submissions.

For the letter of the special issue editor and manuscript submission details please see:

CFP dead line: 31 January 2017




The New York Academy of Sciences - logoThe Biochemical Pharmacology Discussion Group at the New York Academy of Sciences is presenting  a miRNA Symposium with a great speaker line-up:

EVENT:  MicroRNAs: A Gene Silencing Mechanism with Therapeutic Implications

WHEN: July 13, 2016  from 9am – 5:00 pm

The New York Academy of Sciences Conference Center in NYC
7 World Trade Center
250 Greenwich Street, 40th Floor
New York, NY 10007

Keynote Speaker

David Bartel, PhD


Maria Angelica Cortez, PhD
The University of Texas MD Anderson Cancer Center

Paul Grint, MD
Regulus Therapeutics

David S. Hong, MD
The University of Texas MD Anderson Cancer Center

Daniel J. Siegwart, PhD
University of Texas Southwestern Medical Center

Frank Slack, PhD
BIDMC Cancer Center/ Harvard Medical School

Joana Vidigal, PhD
Memorial Sloan Kettering Cancer Center


Here. Webinar is available.

The New York Academy of Sciences miRNA Symposium



And a second webinar this week presented by abcam:


Thursday, June 16, 2016
3pm-4pm CET / 2pm-3pm GMT / 9am-10am EST

Webinar Overview:

Drug‑induced cardiac injury (DICI) detection remains a major safety issue in drug development. While circulating microRNAs (miRs) have emerged as promising translational biomarkers, novel early detection biomarkers of cardiotoxicity are needed to evaluate toxicity in a time-dependent manner.

This webinar will review: [click to continue…]



Wednesday, June 15, 2016
3pm-4pm CET / 2pm-3pm GMT / 9am-10am EST


There are many different types of extracellular vesicles (EVs). Different subpopulations of exosomes, microvesicles and apoptotic bodies have been found to vary in size, composition and intracellular origin.

Within the last decade, cell-secreted EVs have been isolated from most of the fluids of the body, with many laboratories from around the world showing that their composition of lipids, proteins, messenger and micro RNAs are cell-type specific and subject to changes in pathological scenarios. As a result, EVs have been widely studied as a biological source to unravel low invasive biomarkers for predicting, diagnosing and monitoring diseases.
However, despite the many technological advances [click to continue…]


Bioinformatics Resources for MicroRNA Discovery

February 9, 2016

Biomarker identification is often associated with the diagnosis and evaluation of various diseases. Recently, the role of microRNA (miRNA) has been implicated in the development of diseases, particularly cancer. With the advent of next-generation RNA sequencing, the amount of data on miRNA has increased tremendously in the last decade, requiring new bioinformatics approaches for processing […]

Read the full article →

TargetScan7.1 Mouse Released

February 3, 2016

The TargetScan team is excited to announce the official release of the next generation of their microRNA (miRNA) target prediction resource: TargetScan7.1 for the mouse species which can be accessed at . It is a follow-up resource to their paper on major improvements to miRNA target prediction algorithms, published in August 2015 (, and […]

Read the full article →

ThyraMirTM microRNA classifier test for Thyroid Nodules Now Available Through LabCorp

January 12, 2016

PARSIPPANY, N.J., Jan. 12, 2016 /PRNewswire/ — Interpace Diagnostics (NASDAQ: IDXG) announced today that Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), the world’s leading health care diagnostics company, will begin offering Interpace’s new ThyraMirTM microRNA classifier test.  Physicians will be able to order ThyraMir through LabCorp, in addition to Interpace’s ThyGenX® oncogene panel, which LabCorp already […]

Read the full article →

MicroRNA Therapeutic Candidate for the Treatment of NASH in Patients with Type 2 Diabetes/Pre-Diabetes, Enters Phase I Clinical Development

December 18, 2015

Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015 LA JOLLA, Calif., Dec. 18, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by […]

Read the full article →

Upcoming Abcam Webinar: MicroRNAs as biomarkers and therapeutic targets negative breast cancer

December 18, 2015

Upcoming Live Webinar and Q&A Session with Dr Brian D. Adams of Harvard Medical School and sponsorde by Abcam: “MicroRNAs as biomarkers and therapeutic targets in triple negative breast cancer” January 21, 2016 | 11:00am EST/ 8:00am PST Register here Triple negative breast cancer accounts for a disproportionate share of the total breast cancer morbidity […]

Read the full article →